Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.
Dalgleish AG, et al. Among authors: martin aj.
Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11.
Br J Cancer. 2016.
PMID: 27727233
Free PMC article.
No abstract available.